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C-type lectin receptors (CLRs) on antigen-presenting cells (APCs) facilitate uptake of carbohydrate antigens for antigen
presentation, modulating the immune response in infection, homeostasis, autoimmunity, allergy, and cancer. In this review, we
focus on the role of the macrophage galactose type C-type lectin (MGL) in the immune response against self-antigens, pathogens,
and tumor associated antigens (TAA). MGL is a CLR exclusively expressed by dendritic cells (DCs) and activated macrophages
(MØs), able to recognize terminal GalNAc residues, including the sialylated and nonsialylated Tn antigens.We discuss the effects on
DC function induced throughout the engagement of MGL, highlighting the importance of the antigen structure in the modulation
of immune response. Indeed modifying Tn-density, the length, and steric structure of the Tn-antigens can result in generating
immunogens that can efficiently bind to MGL, strongly activate DCs, mimic the effects of a danger signal, and achieve an efficient
presentation in HLA classes I and II compartments.
1. Introduction
Dendritic cells (DCs), as professional antigen-presenting
cells (APCs), sense the microenvironment through different
types of receptors to scan local environmental changes and
eliminate incoming pathogens [1]. They play an essential role
in the uptake of self- or pathogen-associated antigens, thus,
steering and directing the immune response. After activation,
DCsmigrate to the draining lymph nodes, where they initiate
specific immunity. DCs, similarly tomacrophages (MØs) and
B cells, are equipped with a set of receptors that recognize,
capture, and internalize foreign antigens to facilitate an
efficient processing and presentation through MHC II and I
molecules.While B cells are specialized to recognize an exten-
sive variety of epitopes due to the presence of somatically
variable surface immunoglobulin receptors, DCs and MØs
rely on a set of germline-encodedmembrane receptors for the
discrimination and recognition of antigenic determinants.
Besides complement and Fc receptors, DCs express a large
array of pattern-recognition receptors (PRRs), which have
evolved to activate and modulate immune functions upon
encountering ligands from “nonself ” (pathogen-associated
molecular patterns (PAMPs)), “damaged self” (damage-
associated molecular patterns (DAMPs)), or “altered self” as
in cancer (tumor-associated molecular patterns (TAMPs))
[2, 3]. The PRRs are a heterogeneous group of receptor
subfamilies, among which the best characterized are the
toll-like receptors (TLRs) and the C-type lectin receptors
(CLRs). The TLRs respond to a wide variety of pathogen-
derived molecular structures with a response characterized
by the activation of proinflammatory signaling pathways [4].
However, TLRs are not able to internalize antigens. This
function is instead largely covered by CLRs. CLRs were
initially thought to function only as scavenger receptors able
to bind various pathogens upon recognition of particular
carbohydrate profiles through at least one carbohydrate
recognition domain (CRD). CLRs recognize and internalize
specific carbohydrate antigens inCa2+-dependentmanner [5]
thus influencing the outcome of the immune response [6]. In
fact, the importance of C-type lectins is highlighted by the
fact that these receptors are able to trigger numerous cellular
and immunological responses critical for the control and
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Figure 1: Schematic representation of type I and type II C-type lectins and lectin-like receptors. Type I CLRs (MR,DEC-205) are composed of
a N-terminal cysteine-rich domain, a single fibronectin type II (FNII) domain, and 8–10 CTLDs all expressing CRDs. Type II CLRs (Langerin,
DC-SIGN, MGL) or lectin-like receptors (Dectin-1) are composed of a single CTLD, an extracellular stalk region, a transmembrane region,
and a N-terminal cytoplasmic tail with or without a signaling motif or proline-rich region. Langerin, DC-SIGN,MGL, and Dectin-1 express a
CRD on their CTLD. CTLD, C-type lectin like domain; CLR, C-type lectin receptor; CRD, carbohydrate recognition domain; MR, mannose
receptor; DC-SIGN, DC-specific ICAM3-grabbing nonintegrin; MGL, macrophage galactose type C-type lectin.
regulation of infection, homeostasis, autoimmunity, allergy,
and cancer [7–9]. Several studies have demonstrated that
some C-type lectins may function as adhesion, signaling, or
antigen-uptake receptors [10–12].These results are consistent
with the fact that CLRs are present on MØs and DCs, which
play a role in the initial step of capturing the antigens carrying
carbohydrates [13]. Pathogens recognition by CLRs leads
to its internalization, degradation, and subsequent antigen
presentation. Besides antigen recognition and internaliza-
tion, CLRs are also able to induce intracellular signaling
and recruit other molecules such as TLRs that can modulate
the signaling cascade [14]. In particular, CLR triggering by
different pathogens can induce diverse immune responses
[8]. For this reason and for their potential implication in the
therapy of immune diseases and cancer, this receptor family
has received great attention in recent years.
The most important molecules from the CLR family
include macrophage galactose type C-type lectin (MGL),
dendritic cell-specific intercellular adhesion molecule-3-
grabbing nonintegrin (DC-SIGN), mannose receptor (MR),
DEC205, Dectin-1, and Langerin. These receptors are able
to trigger distinct signaling pathways that modulate APC
functions through the expression of specific molecules and
cytokines, determining the polarization of T cells [8].
CLRs such as DC-SIGN, MGL, and Langerin are well
characterized for their specificity for high-mannose, fucose-
containing glycans (LewisA,B,X,Y), GalNAc (N-Acetylgalac-
tosamine) and high mannose, fucose (LewisY, LewisB), and
GlcNAc (N-Acetylglucosamine), respectively (Figure 1) [15,
16]. These glycan structures can be expressed by both mam-
malian cells and pathogens, reflecting CLR dual function in
host-pathogen recognition and immune cell responses.
The APCs are the first line of defence responsible for
clearing pathogens and they subsequently initiate adaptive
immune responses. The DC-expressed C-type lectins man-
nose receptor, DC-SIGN, MGL, Dectin-1, and Langerin on
Langherans cells are involved in glycan-mediated pathogen
recognition and internalization of antigen for loading on
MHC class I and class II molecules, thereby facilitating
effective antigen-specific CD4+ and CD8+ T cell responses
[17]. Thus, most C-type lectins are antigen-uptake receptors
that facilitate MHC-restricted antigen presentation to T cells.
All these lectins are considered powerful signaling molecules
that positively or negatively instruct DC differentiation and
subsequent T cell responses.
In this review, we focus on the role of human MGL as
prototype receptor highly specialized in the glycan recogni-
tion in immune system, on its high plasticity and capacity to
modulate the immune response conditioned by the type of
the ligand.
2. Human MGL in Immune Response
MGL is a CLR exclusively expressed in vivo by human DCs
of skin and lymph nodes and in vitro by macrophages and
monocytes derivedDCs [18, 19].Within theCLR family,MGL
is the only CLRwithin the human immune system that exclu-
sively recognizes terminal 𝛼- or 𝛽 N-acetylgalactosamine
(GalNAc or Tn) residues [20, 21]. In particular, its carbohy-
drate recognition domains contain a QPD sequence that is
responsible for recognition of GalNAc/Tn residues of N- and
O-glycans carried by glycoproteins and/or glycosphingolipids
of helminths, bacteria, filovirus, and tumor-associated anti-
gens [20].
Journal of Immunology Research 3
MGL
hDCs
Self Pathogens
Filovirus: Ebola
Helminths: S. Mansoni, T. suis
Bacteria: C. jejuni, N. gonorrhoeae
Altered self
Tumor-derived
MUC1
MGL ligands
Th2
CTL
Th2
CD45 (effector
T cells and Tregs)
Tregs Tregs
Teff
Figure 2: Representation of ligands binding human MGL expressed by DCs and impact of MGL triggering on immune response.
In mice, there are two homologs of human MGL, MGL1,
and MGL2 [22], expressed by dermal DCs and alternatively
activated macrophages [18, 23]. MGL1 is highly specific for
Lewis X and Lewis A structures, while MGL2, similar to the
human MGL, recognizes N-GalNAc and galactose and O-
linked Tn-antigen, TF-antigen, and core 2 structures [24].
Human MGL is equipped with a partial dileucine zipper,
with YENF internalization motifs [25], and is involved in
(a) the recognition of a large plethora of pathogens by
DCs [26, 27], (b) in the maintenance of homeostasis [28],
and (c) in the interaction with TAA derived from aberrant
glycosylation processes [16, 29]. More recently, our group has
also demonstrated the role of MGL in immunosuppression
given by its capacity to modulate regulatory T cell function
[30] (Figure 2). Thus MGL acts as promiscuous receptor
that can bind more than one ligand modulating various
types of immune response. The pathogens that bind human
MGL include Ebola virus through the interaction with the
viral envelope protein GP2. It was demonstrated that this
lectin promotes filovirus entry suggesting a role for MGL in
viral replication in vivo [31]. Also the helminths Schistosoma
mansoni and Trichuris suis interact with MGL [32, 33].
Schistosoma soluble egg antigens (SEA) consistently are
inducers of Th2 responses in different experimental settings
either in vitro or in vivo and both in humans or in animal
models. In particular, studies performed on DCs have been
instrumental in understanding the polarization of immune
responses towards Th2 by SEA [32, 34–38]. While DCs fail
to show classic signs of maturation when stimulated with
SEA [32, 34], in vitro experiments show that SEA-primed
monocyte-derived DCs (both human and murine) are very
potent in polarizing naiveTh cells towards aTh2 type [34, 35,
38].
DCs show remarkable phenotypic changes when recog-
nizing soluble products (SPs) of Trichuris suis, a pig whip-
worm that is experimentally used in therapies to ameliorate
inflammation in patients with Crohn’s disease and multiple
sclerosis [39]. Trichuris suis glycans play an important role
in the capacity to suppress proinflammatory cytokine and
chemokine production of DCs interacting with DCs via
CLRs, such as MGL. In particular, T. suis SPs suppress the
production of the proinflammatory cytokines, IL-12, TNF-
𝛼, and IL-6, and many proinflammatory chemokines. These
properties, in combination with upregulation of OX40L and
CXCL16 expression, are regarded as positive signals for Th2
polarization [40, 41].
Human MGL, through GalNAc-terminated lipopolysac-
charide (LPS) and glycoproteins, interacts also with bacteria
such as Campylobacter jejuni and Neisseria gonorrhoeae [26,
27]. N. gonorrhoeae phenotype C, carrying a terminal N-
acetylgalactosamine, primarily interacted with MGL and
skewed immunity towards theTh2 lineage through IL-4 pro-
duction, whereas N. gonorrhoeae variant A with a terminal
N-acetylglucosamine on its lipooligosaccharide (LOS) was
recognized by DC-SIGN and induced significantly more IL-
10 production.
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In humans, monocyte-derived DCs express moderate
MGL levels, which become negative after DC maturation.
In addition variation of its expression related to seasonal
changes is observed [42]. Moreover, MGL is upregulated on
tolerogenic DCs generated in the presence of glucocorti-
coids and during chronic inflammatory conditions such as
rheumatoid arthritis, implicatingMGL in immune regulation
[43]. In fact MGL has been shown to interact directly with
a subset of CD4+ and/or CD8+ effector T cells. The MGL
ligand on these T cells was identified as CD45, which exposes
terminal GalNAc (Tn) structures. This interaction negatively
regulates T cell receptor-mediated signaling by decreasing
the phosphatase activity of CD45 and inhibiting lymphocyte
protein tyrosine kinase (Lck) activation and Ca2+ mobiliza-
tion [9] that results in enhanced apoptosis of T cells and
reduced secretion of proinflammatory cytokines [9, 43]. We
have more recently demonstrated that also CD45RA+ Treg
subpopulation is affected by MGL engagement. CD45RA-
MGL cross-linking induces a decrease of Treg immunosup-
pressive activity by affecting CD45RA and TCR signaling and
an increase of Foxp3 methylation accompanied by a reduced
production of suppressive cytokines [30]. Recent evidence
indicates that human MGL expressed on DCs is also able to
generate antigen specific IL-10 producing CD4+ T cells when
stimulated with foreign and self-antigens fused to an anti-
MGL antibody [44].
These results demonstrate an important function for
MGL in the regulation of T cell homeostasis and in the
silencing of potentially harmful T cell activation.
3. MGL in Cancer Immunity
The capacity of CLRs to bind, process, and cross-present
antigens has received much attention in the field of can-
cer immunity. Several of tumor-related glycoforms of self-
antigens are in fact specific ligands for CLRs expressed
on DCs, such as MGL. These evidences open up a new
area of research to investigate whether these tumor specific
glycoforms affect CLR signaling and DC differentiation,
thereby modulating innate and adaptive antitumor response.
MGL is able to recognize the mucin MUC1, an O-linked
glycosylated transmembrane protein normally expressed on
the apical surface of epithelial cells, but aberrantly expressed
in a broad spectrumof carcinomas.Uponmalignant transfor-
mation,MUC1 loses polarity and becomes overexpressed and
aberrantly glycosylated, revealing an immunogenic region of
tandem repeats of 20 residues. The novel MUC1 glycoforms
that arise carry shortened glycan moieties: Tn (GalNAc), T
(Gal𝛽1, 3GalNAc), ST (NeuAc𝛼2, 3Gal𝛽1, and 3GalNAc), and
STn (NeuAc𝛼2, 6GalNAc) [20, 45]. Because MGL recognizes
GalNAc-containing epitopes frequently expressed on the
surface of cancer cells and is involved in the regulation of
the adaptive and innate immune response, it was chosen as
a probe for glycoprofiling in breast cancer. Results indicate
that high MGL-binding molecules in breast were associated
with the expression ofHER2/neu [46, 47]. In particular, it was
demonstrate that detection of Tn ligands in mammary tissue
is feasible employing the MGL recombinant protein and that
this experimental approach permits recognizing posttrans-
lational modifications (PTMs) such as phosphorylation and
glycosylation.The identification of tumor-associated glycans,
which potentially interact with the CRDs, could become a
tool to identify those patientswhowill profit fromMGLbased
specific therapeutic approaches. Tn antigen has previously
been associated with worse survival [48, 49] and recent
research indicates that tumor-specific Tn expression not only
promotes tumor cell invasiveness [50] but also alters the
immunogenicity of tumor antigens [51]. MGL is able to
distinguish healthy tissue from tumor through its specific
recognition of Tn antigen. In vitro studies, using CRC cell
lines, showed an association between MGL ligand expres-
sion and the presence of BRAFV600E, suggesting a model
in which activating BRAF mutations, and possibly other
oncogenic alterations that activate the MAPK pathway, lead
to an altered tumor cell glycosylation profile and enhanced
expression of MGL ligands [48]. These aberrant glycans
on tumor cells may have the ability to suppress antitumor
immune responses through activation of the MGL receptor
on DC. In fact, the prognostic value of MGL-binding to
tumor cells is predominantly evident in stage III of colon
cancer patients and not in stage II patients, that is, when
tumor cells are no longer confined to the intestine but have
spread into the local lymph nodes.
Recently MGL has been shown to bind also STn [21, 52,
53]. Although the binding of glycoproteins carrying Tn has
been investigated [16, 54], the actual role of STn-carrying
proteins binding to MGL is still to be fully investigated.
Highly purified recombinant human MUC1 glycoproteins
and MUC1 glycopeptides carrying either Tn or STn glycans
bind MGL expressed by immature monocyte-derived DCs
and by K562 transfected with MGL [52]. The interaction
with the two glycoforms displays a similar affinity as demon-
strated by atomic force microscopy (AFM).This is important
because, although the vast majority of breast cancers stain
for Tn [50], the 20–25% of breast cancer express the STn
glycoforms on plasma membrane [54].
The most relevant result in tumor is the interaction
between MGL, expressed by DCs, and tumor through the
Tn glycans expressed by MUC1 tumor associated antigen
[16, 29, 55].The signaling activated byMGL has been recently
well characterized in DCs. The MGL engagement with an
anti-MGL antibody or MUC1-Tn glycopeptide (60 amino
acids) triggers the extracellular signal-regulated kinases 1 and
2 (ERK1,2) and nuclear factor-𝜅B (NF-𝜅B) pathways and
induces phenotypic and functional DC maturation to license
DCs to initiate a strong CD8+ T cell immune response [55].
Moreover, similar to other CLRs, MGL signaling synergies
with TLR2-induced pathways in DCs, leading to elevated
IL-10 mRNA levels and enhanced TNF-𝛼 mRNA stability.
In addition, MGL signaling promoted phosphorylation of
the MAPK ERK1,2 and the transcription factor CREB. At
the same time, NF-𝜅B seems to be crucial for the IL-10
response and dispensable for TNF-𝛼 production. Together,
these results demonstrate thatMGL activationmodulates DC
maturation and this ability highlights the possibility to use
this receptor as a target for anticancer vaccination strategies.
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4. The Nature of the Ligand Can Modulate
Signals through MGL
The coupling of CLRs to different signal transduction mod-
ules is influenced not only by the receptor but also by the
nature, density, size, and architecture of the ligand, which can
affect the rate of receptor internalization and trafficking to
different intracellular compartments. Understanding how the
variety of ligands can trigger differential CLR signaling and
function represents a fascinating biological challenge.
MGL was first described as a C-Type lectin with high
endocytic activity regulated by the “YENF” consensus
sequence contained in the cytoplasmic tail. MGL mediated
endocytosis of soluble Tn-carrying antigens resulted in pro-
cessing in HLAII compartment and activation of antigen
specific CD4+ T cells [25, 56]. However these reports did
not investigate the processing in HLAI compartment and
the possible induction of CD8+ T cells responses. The effects
on DCs induced by MGL engagement differ on the basis
of ligands. Employing the Tn-MUC1 glycoform as cancer
model glycoantigen, we showed that the structure of theMGL
ligand dictates the upcoming intracellular processing. In fact,
upon MGL engagement, the large soluble recombinant Tn-
MUC1 glycoprotein (Tn-MUC1
16TR) corresponding to the
one shed in vivo by epithelial cancers remained trapped in
the endolysosomal/HLAII compartment, while the MUC1
peptide (Tn-MUC1
3TR), 60 amino acids long, carrying 9 Tn
moles colocalized both in HLAII and HLAI compartments
[16, 57] (Figure 3(a)).
It is interesting to note that this distinct intracellular
routing of the two MUC1 based ligands matches with a
distinct signaling and phenotypic profile of DCs induced by
MGL engagement.
In fact, cross-processing in HLAI compartment of the
9Tn-MUC1
3TR is accompanied by triggering of ERK1,2
phosphorylation, activation of NF-𝜅B signal, and upreg-
ulation of maturative markers. These effects are similar,
although weaker, to the ones induced by a strong ligand
as a specific anti-MGL MoAb [55], suggesting that MGL
engagement could be used as adjuvant in DC-based vacci-
nation (Figure 3(b)). On the other hand, preliminary and
unpublished results from our laboratory indicate that the
MGL mediated endocytosis of the large soluble Tn-MUC1
molecule, retained in HLAII compartment, does not modify
the balance of ERK1,2/NFkB and DC phenotype. How the
different structure of the ligand and therefore its avidity and
affinity canmodulate intracellular pathway activated byMGL
cytoplasmic tail is yet to be defined. For other C-type lectins
it has been proposed that ligand affinity and avidity as well as
the particulate form of the ligand are crucial for the clustering
of the receptor and the generation of the “endocytic synapsis.”
These steps seem to be important for tuning the strength
of the signaling and determining the type of immunological
response induced [58].
MGL oligomerization appears to occur independently by
the structure of its ligand; however signaling and phenotypic
changes can be different. It has shown that heterodimeriza-
tion with other receptors and association with distinct PPRs
modulate and enhance pathogen sensor function of several
CLRs. MGL has been shown to synergize with TLR2-induced
pathways in a study employing artificial model ligands, not
present in the physiological microenvironment [59]. The
working hypothesis that is sketched out by these evidences
is that the ligand structure is not an absolute requirement for
MGL oligomerization since this event appears to be indepen-
dent of the nature of the ligand (peptide, protein, or single
carbohydrate). However the structure becomes relevant for
the functional outcome. The recruitment of alternative array
of adaptor molecules at the “endocytic synapsis” may be
involved in the differential intracellular sorting of the ligand
and in the tuning of the signaling pathways crucial for DC
polarization.
For this reason, it will be interesting to further charac-
terize the interaction between MGL and its ligand, in terms
of affinity, avidity, and ligand structure in order to design
molecules to be employed as immunomodulators in thera-
peutic strategies for several pathologies, as well as for cancer.
5. Conclusions
The study of MGL and its role in DCs as well as in
macrophage functions is an open interesting area of research.
The specificity for terminal GalNAc residues combined with
the restricted tissue expression of this carbohydrate residue
makesMGL a very specific detector of pathogens and a highly
sensitive modulator of APCs in physiological as well as in
inflammatory and cancer microenvironment.
The engagement of MGL by GalNAc carrying structures
induces oligomerization of the receptor and internalization
of the ligand; however the intracellular signaling pathways
triggered can profoundly vary depending on the structure of
the ligands, differentially affecting function of DCs and the
resulting immune response.
In this view, the possibility to exploit MGL targeting as a
way to modulate APC functions is an appealing hypothesis
for the design of immunotherapeutic intervention.
Avidity and affinity of MGL ligand can be modulated
by modifying Tn-density, the length, and steric structure of
the backbone peptides. For cancer therapy, activation of DCs
could be obtained by mimicking the effects of a danger signal
and achieving an efficient presentation inHLA classes I and II
pathways. Moreover, a wide variety of immunogens carrying
Tn-epitopes could be envisaged, where the Tn-peptide stretch
could only be a way to deliver other TAAs as well as other
molecules. On the other hand, the fine-tuning of MGL func-
tion could lead to the induction of “Th2 oriented DCs” and
interfere in the immunosuppressive/inflammatory network
induced by pathogens infection. So far, investigators have
focused their attention on the understanding the effect of
MGL engagement on DCs. However, one has to bear in mind
that the MGL-GalNAc ligand engagement mediates a one to
one interaction between two cells. Thus functional changes
may also occur in the cell carrying the GalNAc moieties.
This mechanism seems to be particularly relevant in the
physiological tissue homeostasis such as in T cell compart-
ment. In this prospective, the design of optimal immunother-
apeutic molecules based on MGL triggering could be novel
approaches for the treatment of autoimmune diseases.
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Figure 3: The structure of tumor antigen formulations internalized by MGL influences their processing and DC performance. (a)
Recombinant Tn-MUC1
16TR protein remains blocked inDCsHLA class II compartment after internalization throughMGL, while the shorter
Tn-MUC1
3TR peptide (60 amino acids) is processed in HLA classes I and II compartments. (b) Effects induced on DC functions by MGL
engagement with MoAb anti-MGL and Tn-MUC1 peptide.
It is also important to retain that the molecular targeting
and the choice of the antigen represent only “one side of
the coin” in designing immunotherapeutic approaches. The
choice of the optimal DC subset for priming T cells and
strategies to contain or eliminate immunosuppression are
other crucial parameters that should be considered to obtain
an efficacious and long-lasting immune response.
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